COMP <GO>
AGIO vs JNJ // 10Y YIELD & FRED MACRO BETA
Agios Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: AGIO 3
— JNJ 7
■ METRIC PARITY
LAST: $30.55 (-17.94%) • MKT CAP: $2.22B
macro-sensitivity
—
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGIO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGIO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.30% | 67.90% | +20.40 | AGIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -33.80% | 25.50% | -59.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.97% | 2.97% | -19.94 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 48.00% | 6.00% | +42.00 | AGIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.84 | 5.59 | +6.25 | AGIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 62.1 | -5.50 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.22B | $662.49B | -$660.27B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGIO REV | JNJ REV | AGIO GROSS % | JNJ GROSS % | AGIO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $54.0M | $94.19B | 88.3% | 67.9% | -$377.3M | $19.70B |
| FY 2024 | $36.5M | $88.82B | 88.6% | 69.1% | -$391.5M | $19.84B |
| FY 2023 | $26.8M | $85.16B | — | — | -$296.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGIO // BETA —
JNJ // BETA 1.08